CROs using purpose-built clinical applications and data to streamline
end-to-end processes
PLEASANTON, Calif.--(BUSINESS WIRE)--
According to a global industry survey from Veeva
Systems (NYSE: VEEV), contract research organizations (CROs) are
leading an industrywide shift to modernize clinical systems and
streamline end-to-end trial processes. The Veeva
2017 Unified Clinical Operations Survey: CRO Report reveals
that CROs are making progress in moving away from manual processes and
legacy systems and increasingly adopting purpose-built clinical
applications. However, all CROs surveyed report the need to unify their
clinical applications, including their CTMS, EDC, and eTMF, to speed
study execution, reduce cost, and improve study quality.
Modernizing Clinical Systems and Processes
Overall, CROs utilize more clinical applications than sponsors to manage
their trial processes, with 50% of CROs using five applications or more
compared to 38% of sponsors. Among all clinical applications, EDC (86%)
is the most commonly used among CROs, followed by eTMF (62%).
However, application and process silos are creating significant
difficulties, with nearly three quarters (72%) of CROs reporting
integration of multiple applications as the biggest challenge they face
with their clinical solutions.
In fact, nearly all (96%) CROs say challenges with their current CTMS
application limit their ability to improve clinical operations.
Integration with EDC (50%) is one of their most frequently reported
issues, and two-thirds of top CROs (64%) say integration with eTMF is
also a challenge.
Despite these challenges, CROs are modernizing their clinical
environments at an accelerated pace compared to sponsors. More CROs
(42%) use a purpose-built eTMF application versus sponsors (31%) and a
third (32%) of CROs are adopting study start-up applications faster,
compared to only 9% of sponsors.
Leveraging Data to Improve Trial Processes
The use of data and metrics is key to improving trial processes. This is
an area where CROs are leading the industry, as the survey found that a
third (35%) of CROs extensively use eTMF data compared to a quarter
(27%) of sponsors. CROs that extensively use data to improve trial
processes reported greater benefits, including better visibility into
performance metrics (59%) and automated tracking and reporting of
documents (65%).
However, one third (30%) of CROs still report challenges with clinical
data being tracked outside of clinical systems. This is likely due to
technology limitations such as system silos and poor integration.
Consequently, reporting across multiple applications is one of the
biggest challenges CROs face when asked about their use of clinical
systems. That is why half (54%) of CROs report the need for better
visibility.
“There is an overwhelming need to address the application and process
silos that are holding the industry back,” said Jennifer Goldsmith,
senior vice president of Veeva Vault. “CROs are taking significant steps
to modernize the clinical environment and playing a pivotal role in
moving the industry toward a unified operating model.”
The Veeva
2017 Unified Clinical Operations Survey: CRO Report examines
CROs’ progress in unifying clinical operations by gathering the
experiences and opinions of 50 CRO respondents from around the world.
This research examines the drivers, barriers, and benefits of a unified
clinical operating model and tracks the move to streamline clinical
systems and processes.
To hear more about how both sponsors and CROs are addressing the shift
towards a unified clinical landscape, join more than 1,000 life science
leaders and industry experts at the 2017
Veeva Global R&D Summit in Philadelphia on October 2 – 4. Learn
more about the event and register
today.
Additional Information
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veevasystems on Twitter: twitter.com/veevasystems
Like Veeva on Facebook: facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is a leader in cloud-based software for the global
life sciences industry. Committed to innovation, product excellence, and
customer success, Veeva has more than 550 customers, ranging from the
world's largest pharmaceutical companies to emerging biotechs. Veeva is
headquartered in the San Francisco Bay Area, with offices in Europe,
Asia, and Latin America. For more information, visit veeva.com.
Forward-looking Statements
This release contains forward-looking statements, including the market
demand for and acceptance of Veeva’s products and services, the results
from use of Veeva’s products and services, and general business
conditions, particularly in the life sciences industry. Any
forward-looking statements contained in this press release are based
upon Veeva’s historical performance and its current plans, estimates,
and expectations, and are not a representation that such plans,
estimates, or expectations will be achieved. These forward-looking
statements represent Veeva’s expectations as of the date of this press
announcement. Subsequent events may cause these expectations to change,
and Veeva disclaims any obligation to update the forward-looking
statements in the future. These forward-looking statements are subject
to known and unknown risks and uncertainties that may cause actual
results to differ materially. Additional risks and uncertainties that
could affect Veeva’s financial results are included under the captions,
“Risk Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations,” in the company’s filing on Form
10-Q for the period ended April 30, 2017. This is available on the
company’s website at veeva.com
under the Investors section and on the SEC’s website at sec.gov.
Further information on potential risks that could affect actual results
will be included in other filings Veeva makes with the SEC from time to
time.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170906005737/en/
Source: Veeva Systems Inc.